Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 12/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL408707 | 0.84 | PDE4B (0.50) | DGAT1KDM4EALDH1A1MAPK1NPSR1 | |
| SCHEMBL408204 | 0.83 | DGAT1 (0.41) | DGAT1LMNA | |
| SCHEMBL407653 | 0.82 | DGAT1 (0.49) | DGAT1KDM4EALDH1A1GAAMAPK1 | |
| SCHEMBL407225 | 0.81 | DGAT1 (0.48) | DGAT1KDM4EALDH1A1LMNAMAPK1 | |
| SCHEMBL442691 | 0.81 | DGAT1 (0.61) | DGAT1KDM4EALDH1A1LMNAGAA | |
| SCHEMBL407661 | 0.79 | DGAT1 (0.47) | DGAT1KDM4EALDH1A1LMNAGAA | |
| SCHEMBL407229 | 0.79 | DGAT1 (0.45) | DGAT1KDM4EALDH1A1LMNACA12 | |
| SCHEMBL4486967 | 0.78 | DGAT1 (0.52) | DGAT1KDM4EALDH1A1LMNACA12 | |
| SCHEMBL408365 | 0.78 | DGAT1 (0.59) | DGAT1KDM4EALDH1A1LMNACA12 | |
| SCHEMBL24303811 | 0.78 | CA12 (0.56) | DGAT1KDM4EALDH1A1LMNACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | DGAT2, DGAT1, DLAT | DGAT1 2/4885KDM4E 2452/4885ALDH1A1 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.